These findings suggest that CD90(+) CTC dynamics are strongly linked to tumor response and prognosis in unresectable HCC when treated with Atezo + Bev or lenvatinib, highlighting their potential as valuable biomarkers. The gene discussed is THY1; the disease is hepatocellular carcinoma.